Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ovapuldencel-T
- Development stage
- Unknown
- Lead developer
- Aivita Biomedical
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Ovapuldencel-T (AV-OVA-1) is a patient-specific, autologous dendritic cell vaccine developed by Aivita Biomedical (formerly California Stem Cell and Caladrius Biosciences) for the treatment of advanced ovarian cancer. The vaccine consists of autologous dendritic cells loaded ex vivo with autologous tumor antigens derived from a lysate of irradiated self-renewing cells enriched for tumor-initiating cells (TICs) isolated from the patient's own tumor tissue. Prior to subcutaneous administration, the vaccine is admixed with granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant. This personalized immunotherapy is designed to stimulate a robust, patient-specific cytotoxic T-lymphocyte (CTL) immune response targeting the unique repertoire of neoantigens and tumor-associated antigens present on the patient's ovarian cancer cells, particularly the tumor-initiating cells responsible for disease recurrence and progression.
- Other names
- Autologous dendritic cells loaded with autologous tumor antigensAutologous dendritic cells loaded with autologous tumor associated antigensPersonal cancer vaccinePersonal cancer vaccine (ovarian)Personal cancer vaccine - OvarianPersonal dendritic cell vaccine for ovarian cancer
02
Targets
MAGEA8 (Melanoma-associated antigen 8)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on ovapuldencel-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ovapuldencel-T.